All In Biotech

Drug Trial Radar · NCT06143878

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 774 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

774

Actual

Start

Jan 17, 2024

Primary completion

Sep 17, 2024

Study completion Jun 1, 2027

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Nov 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.

Conditions

  • Plaque Psoriasis

Interventions

  • JNJ-77242113Drug

    JNJ-77242113 will be administered orally.

  • JNJ-77242113 Matching PlaceboDrug

    JNJ-77242113 matching placebo will be administered orally.

  • DeucravacitinibDrug

    Deucravacitinib will be administered orally.

  • Deucravacitinib Matching PlaceboDrug

    Deucravacitinib matching placebo will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and a Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16Time frame: Week 16
  2. Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 at Week 16Time frame: Week 16

Locations

164 sites in 13 countries. Site status is shown where the registry gives one.

  • Medical Dermatology Specialists

    Phoenix, Arizona

  • Center for Dermatology and Plastic Surgery

    Scottsdale, Arizona

  • Johnson Dermatology

    Fort Smith, Arkansas

  • First OC Dermatology

    Fountain Valley, California

  • Center for Dermatology Clinical Research

    Fremont, California

  • Integrative Skin Science and Research

    Sacramento, California

  • Southern California Dermatology

    Santa Ana, California

  • Clinical Science Institute

    Santa Monica, California

  • Driven Research LLC

    Miami, Florida

  • Ziaderm Research LLC

    North Miami Beach, Florida

  • Renstar Medical Research

    Ocala, Florida

  • Forcare Clinical Research Inc

    Tampa, Florida

  • Hamilton Research LLC

    Alpharetta, Georgia

  • Skin Care Physicians of Georgia

    Macon, Georgia

  • DeNova Research

    Chicago, Illinois

  • Arlington Dermatology

    Rolling Meadows, Illinois

  • Endeavor Health

    Skokie, Illinois

  • Dundee Dermatology

    West Dundee, Illinois

  • Dawes Fretzin Clinical Research Group LLC

    Indianapolis, Indiana

  • Indiana Clinical Trial Center

    Plainfield, Indiana

  • Dermatology Specialists

    Louisville, Kentucky

  • Dermatology and Advanced Aesthetics

    Lake Charles, Louisiana

  • Tufts Medical Center

    Boston, Massachusetts

  • David Fivenson MD, Dermatology

    Ann Arbor, Michigan

  • Michigan Center of Medical Research

    Clarkston, Michigan

  • Henry Ford Medical Center

    Detroit, Michigan

  • Hamzavi Dermatology

    Fort Gratiot, Michigan

  • MediSearch Clinical Trials

    Saint Joseph, Missouri

  • Skin Specialists

    Omaha, Nebraska

  • Fife Dermatology

    Las Vegas, Nevada

  • StracSkin

    Portsmouth, New Hampshire

  • Schweiger Dermatology Group

    East Windsor, New Jersey

  • Schweiger Dermatology Group 1

    Hackensack, New Jersey

  • Derm Research Center of New York, Inc.

    Stony Brook, New York

  • Wilmington Dermatology Center

    Wilmington, North Carolina

  • Oakview Dermatology

    Athens, Ohio

  • Optima Research

    Boardman, Ohio

  • Central Sooner Research

    Oklahoma City, Oklahoma

  • Oregon Medical Research Center

    Portland, Oregon

  • Health Concepts

    Rapid City, South Dakota

Showing 40 of 164 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.